Phase 2 Carcinoma, Non-Small-Cell Lung trials recruiting now

All Carcinoma, Non-Small-Cell Lung trials, every phase

Other phases for Carcinoma, Non-Small-Cell Lung

Phase 2 Carcinoma, Non-Small-Cell Lung trials

• A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
  NCT06380816 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
  NCT07227025 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 13 locations
• A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
  NCT06667076 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 203 locations
• A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
  NCT05498428 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 110 locations
• A Study of DM005 in Patients With Advanced Solid Tumors
  NCT06515990 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
  NCT06780085 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 34 locations
• A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
  NCT06667908 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 43 locations
• A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
  NCT05456256 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 16 locations
• A Study of Navlimetostat (BMS-986504) in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)
  NCT06855771 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 70 locations
• A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
  NCT07586202 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 20 locations
• A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
  NCT07154290 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 16 locations
• A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC
  NCT05940532 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC
  NCT06709859 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
  NCT05768178 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 16 locations
• DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
  NCT07440290 · Phase: Phase 2, Phase 3 · Ages: 1 Year and older · Sex: All (male and female) · 27 locations
• Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
  NCT04499053 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy
  NCT05715229 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Intratumoral N17350 in Advanced Solid Tumors
  NCT07339176 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 16 locations
• KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
  NCT04165070 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 46 locations
• Locally Advanced NSCLC Treated With Radiochemotherapy: Phase 2 Study on the Value of a Stereotactic Boost
  NCT06627738 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer with EGFR Mutation and PD-L1 Positive Expression
  NCT06269211 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC
  NCT06623656 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
  NCT04486833 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
  NCT07227298 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 73 locations

Common questions

What does Phase 2 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.